Research Paper Volume 13, Issue 8 pp 11096—11119
Pan-cancer analysis identifies ITIH1 as a novel prognostic indicator for hepatocellular carcinoma
- 1 Department of Internal Medicine, The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China
- 2 Department of Radiology, The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China
- 3 Department of Hepatology, The Affiliated Third Hospital of Jiangsu University, Zhenjiang, China
- 4 Laboratory Center, Affiliated People’s Hospital of Jiangsu University, Zhenjiang, China
Received: November 2, 2020 Accepted: January 22, 2021 Published: March 21, 2021https://doi.org/10.18632/aging.202765
How to Cite
Copyright: © 2021 Chang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Although a previous pan-cancer study has reported the expression patterns of ITIHs in various tumors, their analyses have been restricted to limited cancer types. We thus comprehensively analyzed the expression profiles and clinical significances of ITIHs in a broader spectrum of cancers from TCGA. Our results showed that ITIHs were primarily down-regulated in tested cancers. The ITIH members were associated with either survival advantage or disadvantage, depending on the cancer type tested and the genes queried. Importantly, we for the first time demonstrated that ITIH1 had substantially decreased expression in liver hepatocellular carcinoma (LIHC) compared with corresponding normal tissue, and its down-regulation adversely impacted patient outcome. Moreover, ITIH1 expression was consistently declining during the progression of LIHC. Further analysis revealed that ITIH1 may be involved in cellular metabolic processes. Our findings established ITIH1 as a potential diagnostic and prognostic biomarker for LIHC, which awaits future experimental validation.